For immediate release

Seinäjoki, Finland 12.02.2025

Stein Ulve reorganized his shareholdings today by selling his 2,726,717 shares in Eevia Health to Orcator Oy, a holding company wholly (100%) owned by Stein Ulve's spouse. The price was two euro cents per share, and in exchange, Stein Ulve received shares in Orcator Oy, resulting in him and his spouse holding a 50% stake each in the holding company. Orcator Oy should be recognized as a Person Closely Associated (PCA), not an "external investor."

Additionally, Orcator Oy has acquired 219,450 shares and subscription rights for 1.5 euro cents per share and 31,350 Warrants TO1 for 0.15 euro cents per warrant in off-market transactions. As a result, Orcator Oy now holds 2,946,167 shares, representing 4.39% of Eevia's current total outstanding shares.

Further demonstrating Stein Ulve's (and Orcator Oy's) commitment to Eevia's prospects and financial outlook, Orcator Oy has also subscribed for its pro-rata portion of shares in the ongoing rights Issue, amounting to 5,892,334 new shares, equaling an investment of c. KSEK 530.

Orcator Oy has previously provided a KEUR 200 guarantee commitment in the current rights issue in Eevia. If the guarantee were called upon, it would provide subscription of 25,974,026 shares, or 19,4% of the total shares offered in the rights issue. Together with today's subscription, the underwriting commitments are for a total of 31,866,360 shares or 23,8% of the total offering of 134,111,190 shares in the rights issue. Together with guarantee commitments from other investors, 31,8% of the rights issue is secured.

"I am excited and confident about Eevia's future. The current Board has supported Management in carving out an ingenious and future oriented plan to target tremendous and relevant market opportunities for our core strengths. The subscription made today is my vote of strong confidence in the plan for Eevia 2.0, which leverages what we have learned to address real human health challenges supported by nature and leading nutritional science. I see a huge value upside in our venture, and hope shareholders and investors can see the same," says Stein Ulve, Eevia's CEO.  

This disclosure contains information that EEVIA HEALTH PLC must make public according to the EU Market Abuse Regulation (EU nr 596/2014). The information was initially submitted for publication through the contact person's agency on February 12, 2025, at 13:20 EST.

For further information, please contact:

Stein Ulve, CEO, Eevia Health Plc                          

Email: stein.ulve@eeviahealth.com or investor@eeviahealth.com                  

Telephone: +358 400 22 5967                                

INFORMATION ABOUT EEVIA HEALTH PLC

Eevia Health Plc, founded in March 2017, addresses significant health problems with bioactive compounds extracted from plant materials. The materials are primarily wild harvested from the pristine Finnish and Swedish forests near or above the Arctic Circle. The extracts are sold B2B as ingredients in dietary supplements and food brands globally, and these global brands utilize the ingredients in their consumer product formulas.

Eevia Health manufactures 100% organically certified plant extracts. Although a significant product, Elderberry extract, is made from cultivated berries, most of Eevia's other raw materials, such as bilberry, lingonberry, chaga, and pine bark, are wild-harvested sustainably.

Eevia Health operates a modern green-chemistry production facility in Finland. Manufacturing natural ingredients near the raw material harvest areas, Eevia offers a short value chain with an environmentally friendly carbon footprint, competitive pricing, and extreme transparency. In June 2021, Eevia listed its shares on the Spotlight Stock Market in Sweden under the short name (ticker) EEVIA.

To learn more, please visit  www.eeviahealth.com or follow Eevia Health on LinkedIn@EeviaHealth.